Key result
Co-injecting a nitric oxide synthase inhibitor cuts microvascular blood flow response to lidocaine by ~60%.
Why the study?
Do nitric oxide release, the cyclo-oxygenase pathway, or beta-adrenoceptors influence the microvascular blood flow response to intradermal lidocaine in healthy male volunteers?
Do nitric oxide release, the cyclo-oxygenase pathway, or beta-adrenoceptors influence the microvascular blood flow response to intradermal lidocaine in healthy male volunteers?
Nitric oxide release, but not cyclo-oxygenase or beta-adrenoceptor pathways, contributes significantly to the vasodilator vasoactivity of intradermal lidocaine in human skin.
Answers are grounded in this paper and cite their sources.
NO mediates lidocaine skin vasodilation; extends mechanistic understanding but leaves clinical relevance open.
The vasodilator properties of lidocaine are believed to be due mainly to the inhibition of action potentials via sodium channel blocking in vasoconstrictor sympathetic nerves. However, mechanisms involving the vascular endothelium may also play a role, and in this study we investigated the potential influences of nitric oxide release, the cyclo-oxygenase pathway and the beta-adrenoceptors of vascular smooth muscle. Laser Doppler imaging was used to measure microvascular blood flow responses to intradermal injection of lidocaine 2%, with or without the addition of preservatives, in eight healthy, male volunteers. Co-injection of the nitric-oxide-synthase inhibitor Nomega-nitro-L-arginine methyl ester caused a 60% reduction in the response after about 20 min, and this reduction was enhanced with the lidocaine solution containing the preservatives methylhydroxybenzoate and propylhydroxybenzoate. No reduction in response was seen after blocking the cyclo-oxygenase or beta-adrenoceptor pathways. Nitric oxide release contributes to the vasoactivity of lidocaine in human skin.
No takes yet. Share an insight, caveat, or question.
Newton et al. (2006) studied Healthy volunteers (n=8). Intradermal injection of lidocaine was evaluated on Microvascular blood flow responses (60% reduction). Co-injection of the nitric-oxide-synthase inhibitor Nomega-nitro-L-arginine methyl ester caused a 60% reduction in the microvascular blood flow response to intradermal lidocaine 2%.
Synapse has enriched 10 related papers. Consider them for comparative context: